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Functional micropeptides can be concealed within
RNAs that appear to be noncoding. We discovered
a conserved micropeptide, which we named myore-
gulin (MLN), encoded by a skeletal muscle-specific
RNA annotated as a putative long noncoding RNA.
MLN shares structural and functional similarity with
phospholamban (PLN) and sarcolipin (SLN), which
inhibit SERCA, the membrane pump that controls
muscle relaxation by regulating Ca2+ uptake into the
sarcoplasmic reticulum (SR). MLN interacts directly
with SERCA and impedes Ca2+ uptake into the SR.
In contrast to PLN and SLN, which are expressed in
cardiac and slow skeletal muscle in mice, MLN is
robustly expressed in all skeletal muscle. Genetic
deletion of MLN in mice enhances Ca2+ handling in
skeletal muscle and improves exercise performance.
These findings identifyMLNasan important regulator
of skeletalmuscle physiology and highlight the possi-
bility that additional micropeptides are encoded in
the many RNAs currently annotated as noncoding.
INTRODUCTION
Ca2+ controls the normal function of striated muscle by acting as
theprimary regulator of the sarcomeric contractilemachinery and
as a second messenger in the signal transduction pathways that
control muscle growth, metabolism, and pathological remodel-
ing (Bassel-Duby and Olson, 2006; Berchtold et al., 2000). Ca2+
handling in striated muscle is tightly regulated by Ca2+ pumps
in the sarcoplasmic reticulum (SR) and plasma membranes that
maintain intracellular Ca2+ levels 10,000-fold lower than extra-
cellular and SR concentrations (Berridge et al., 2003; Rossi and
Dirksen, 2006). Upon muscle stimulation, Ca2+ release by the
ryanodine receptor (RyR) in the SR membrane transiently in-
creases Ca2+ levels in the cytosol, triggering actomyosin cross-
bridge formation within the sarcomere to generate contractile
force. Reuptake of Ca2+ into the SR by sarcoplasmic reticulumCa2+-ATPase (SERCA) is necessary for muscle relaxation and
restores SR Ca2+ levels for subsequent contraction-relaxation
cycles. SERCA serves as a central regulator of striated muscle
performance and the pathological signaling pathways that drive
cardiovascular and skeletalmuscle disease (Dorn andMolkentin,
2004; Goonasekera et al., 2011; Odermatt et al., 1996; Pan et al.,
2003; Periasamy and Kalyanasundaram, 2007).
Two related peptides, phospholamban (PLN) and sarcolipin
(SLN), directly interact with SERCA in the SRmembrane to regu-
late Ca2+ pump activity (Kranias and Hajjar, 2012; MacLennan
and Kranias, 2003). PLN and SLN are expressed in partially over-
lapping patterns in cardiac and slow skeletal muscle and are
important regulators of muscle performance and cardiovascular
disease (Briggs et al., 1992; Kranias and Hajjar, 2012; Minami-
sawa et al., 2003; Schmitt et al., 2003; Tada and Toyofuku,
1998; Tupling et al., 2011). PLN-deficient mice exhibit enhanced
myocardial contractile performance, characterized by increased
ventricular relaxation rates and SERCA pump activity (Chu et al.,
1998; Luo et al., 1994). Similarly, loss of PLN or SLN expression
significantly increases the rate of muscle relaxation and SERCA
pumpactivity in slowskeletalmuscle but doesnot affect fast skel-
etalmuscles,whichdonot expressPLNorSLN (Slacket al., 1997;
Tupling et al., 2011;Vangheluweet al., 2005). Theabsenceof PLN
and SLN expression in fast skeletal muscle, the dominant muscle
type in mice, suggests that an unidentified factor regulates Ca2+
handling and the contractile performance of this tissue.
Recent genome-wide studies have suggested that hundreds
of functional micropeptides may be encoded in vertebrate long
noncoding RNAs (lncRNAs) (Andrews andRothnagel, 2014; Baz-
zini et al., 2014). The microproteome has largely been over-
looked in gene annotations, primarily because of the difficulty
in identifying functional small open reading frames (ORFs) in
RNA transcripts. While analyzing an annotated skeletal
muscle-specific lncRNA, we discovered a previously unrecog-
nized ORF encoding a conserved 46 amino acid micropeptide,
which we named myoregulin (MLN). MLN forms a single trans-
membrane alpha helix that interacts with SERCA in the mem-
brane of the SR and regulates Ca2+ handling. Consistent with
this function, deletion of MLN in mice significantly enhances
Ca2+ handling and improves exercise performance. These
findings identify MLN as the predominant SERCA-inhibitoryCell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc. 595
Figure 1. Discovery of a Skeletal Muscle-
Specific Micropeptide
(A) A short ORF encoding a conserved micro-
peptide, which we named myoregulin (MLN), is
contained within exon 3 of an annotated lncRNA in
human and mouse genomes. The position of the
MLN ORF is indicated in red.
(B) In situ hybridization showing skeletal muscle-
specific expression of MLN at the indicated em-
bryonic time points. hrt, heart; in, intestine; liv,
liver; lu, lung; m, myotome; to, tongue.
(C) Northern blot of RNA isolated from adult mouse
tissues using a probe specific to the full-length
MLN transcript shows skeletal muscle-specific
expression.
(D) Diagram of the constructs used for in vitro
translationof theMLNmicropeptide. The full-length
MLN RNA transcript was subcloned into the CS2
vector containing the SP6 phage RNA polymerase
promoter (SP6-MLN). A frameshift mutation was
introduced immediately after the endogenous ATG
to disrupt the MLN ORF (SP6-MLN-FS).
(E) Coupled in vitro transcription and translation
reactions of the SP6-MLN vector using radio-
labeled 35S-methionine produced a 5 kDa mi-
cropeptide, visualized by Tricine SDS-PAGE. The
frameshift mutation in the MLN ORF (SP6-MLN-
FS) abolished any detectable expression.
(F) Targeting strategy using CRISPR/Cas9-medi-
ated homologous recombination to knock in a
FLAG epitope tag into the MLN locus in C2C12
cells. PCR-based genotyping using primers (P1–
P3) or RFLP analysis of PCR products generated
using primers (P4 and P5) was used to verify
correct targeting.
(G) RFLP analysis of WT C2C12 and heterozygous C2C12 myoblasts for the MLN-FLAG knockin allele.
(H) Western blot analysis showing endogenous expression of the MLN-FLAG fusion peptide in differentiated C2C12 myotubes, detected with an anti-FLAG
antibody.
See also Figure S1.micropeptide in skeletal muscle, which surprisingly was con-
cealed in an RNA annotated as noncoding.
RESULTS
Discovery of a Conserved Micropeptide Encoded by a
lncRNA
In a bioinformatic screen for uncharacterized skeletal muscle-
specific genes, we identified a vertebrate RNA transcript anno-
tated as a lncRNA (LINC00948 in humans and 2310015B20Rik
in mice). Analysis of the evolutionary conservation of these tran-
scripts identified a short 138 nucleotide ORFwith the potential to
encode a highly conserved 46 amino acid micropeptide, which
we named myoregulin (MLN) (Figure S1A available online). The
human and mouse MLN genes consist of three exons that
span 16.5 and 15.0 kb, respectively, with the ORF located in
exon 3 (Figure 1A). Nucleotide insertions and deletions that could
alter the reading frame flank the MLN ORF, demonstrating that
these sequences comprise UTRs (Figure S1A).
During embryogenesis, MLN is expressed in the myotomal
compartment of the somites, the anlagen of skeletal muscle (Fig-
ure 1B). During fetal and adult stages, MLN is robustly expressed
in all skeletal muscles and is not detectable in cardiac or smooth596 Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc.muscles (Figures 1B and 1C). MLN transcripts are also present in
C2C12 myoblasts and myotubes, but not in 10T1/2 fibroblasts
(Figure S1B).
To determine if the MLN ORF is translated as a micropeptide,
we transcribed and translated the full-length MLN RNA in vitro
in the presence of radiolabeled 35S-methionine (Figures 1D
and 1E). A single 5 kDa micropeptide was produced from the
MLN transcript, whereas a frameshift mutation that disrupted
the MLN ORF abolished any detectable expression (Figures 1D
and 1E). We further cloned a FLAG epitope tag in-frame with
the C terminus of theMLN coding sequence within the full-length
MLN transcript (Figure S1C). Expression of this construct in
COS7 cells yielded a peptide of 6 kDa, corresponding to the
predicted molecular weight of the MLN-FLAG fusion peptide,
detected by western blot (Figure S1D).
To determine whether MLN is endogenously expressed in
skeletal muscle, we introduced the same FLAG epitope tag
into the MLN locus in C2C12 muscle cells using CRISPR/
Cas9-mediated homologous recombination (Figures 1F and
S1E). PCR-based genotyping and restriction fragment-length
polymorphism (RFLP) analyses were used to verify correct tar-
geting (Figures 1G and S1F). As shown by western blot analysis
in Figure 1H, C2C12 cells heterozygous for the MLN-FLAG
Figure 2. MLN Forms a Transmembrane
Alpha Helix that Interacts with SERCA
(A) The secondary structure (SS) of MLN is pre-
dicted to contain an N-terminal beta sheet and
C-terminal transmembrane alpha helix (E, beta
sheet; H, alpha helix). Alignment of mouse MLN,
PLN, SLN, and the invertebrate ortholog SCL
identified identical (green) and similar (blue) resi-
dues conserved in all four micropeptides.
(B) The structure of the transmembrane helices
of MLN, SLN, PLN, and SCL was modeled using
I-TASSER and showed a common spatial orien-
tation of conserved residues.
(C) Automated protein docking using ClusPro
predicted that MLN occupies the same groove in
SERCA1 that is recognized by SLN.
(D) Two-photon laser scanning confocal micro-
scopy showing colocalization of GFP-MLN and
mCherry-SERCA1 fusion proteins in the SR of
mature skeletal muscle fibers. M, M-line; Z, Z-line.
(E) Retroviral expression of an N-terminal HA-
tagged MLN fusion peptide (HA-MLN) in C2C12
myoblasts was enriched in the subcellular fraction
containing SR/ER membrane proteins. Enrich-
ment for cytosolic, SR/ER membrane, and plasma
membrane proteins was verified by western
blot analysis for Hsp90, PDI, and N-cadherin,
respectively.
(F) Coimmunoprecipitation (coIP) experiments
with HA-tagged MLN alanine mutants and a Myc-
tagged SERCA1 construct transfected into COS7
cells identified residues important for interaction
of MLN with SERCA1. Interaction of MLN with
SERCA1 was abolished by mutation of residues
shared with PLN, SLN, and SCL (L29A, F30A, and
F33A), but not by the charged residues K27A or
D35A. Western blot performed with anti-HA (WB-
HA) or anti-Myc (WB-Myc).
See also Figure S2.knockin allele expressed amicropeptide of the predicted molec-
ular weight of the MLN-FLAG fusion peptide. Together, these
data reveal that the MLN RNA, which is annotated as noncoding,
in fact encodes a cryptic micropeptide.
MLN Encodes a Transmembrane Alpha Helix
The MLN micropeptide is highly conserved across mammals
and is predicted to form a type II single-pass transmembraneCell 160, 595–606,alpha helix in which the 19 N-terminal
amino acid residues are exposed to
the cytosol and the three C-terminal res-
idues are lumenal (Figures 2A and S2A).
The N-terminal residues (5–10) of MLN
are predicted to fold into a small beta
sheet, and the C-terminal half of the
protein contains the predicted trans-
membrane alpha helix (Figures 2A and
S2A). Circular dichroism spectroscopy
measurements of synthesized full-length
MLN peptide in detergent micelles
confirmed it consists of alpha helix(43.6%), beta sheet (21.1%), turn (9.6%), and random coil
(25.7%) structures (Figure S2B).
Association of MLN with SERCA
MLN shows a strong structural resemblance to PLN and SLN,
which also form type II single-pass transmembrane peptides ori-
ented with their N-terminal residues exposed to the cytosol.
Sequence alignment of MLN, PLN, and SLN revealed a numberFebruary 12, 2015 ª2015 Elsevier Inc. 597
Figure 3. MLN Regulates SR Ca2+ Levels by
Inhibiting SERCA Pump Activity
(A and B) The Ca2+ dependence of the relative rate
of Ca2+ uptake is shown for homogenates from
HEK293 cells cotransfected with SERCA1 and the
indicated constructs. Cotransfection with MLN,
PLN, or SLN resulted in a similar decrease in Ca2+
uptake, corresponding to a decreased affinity
of SERCA for Ca2+, relative to empty vector
(Control). For comparison, untransfected cells
and SERCA1-expressing cells treated with the
SERCA inhibitor thapsigargin (100 nM) are shown.
The activity of the full-length RNA transcript en-
coding the MLN ORF (MLN RNA) is abolished
by a frameshift mutation in the MLN ORF (MLN-
RNA FS).
(C) Retroviral cotransduction of C2C12 myoblasts
with the FRET-based Ca2+ sensor T1ER with MLN
or SLN was used to directly measure the relative
levels of SR Ca2+. Both MLN and SLN significantly
decreased SR Ca2+ levels relative to an empty
retroviral vector.
(D) Retroviral overexpression of MLN or SLN in
C2C12 myoblasts treated with 4-CMC and
imaged with fura-2-AM showed decreased levels
of SR Ca2+, measured by peak Ca2+ release from
the SR.
Data are presented as mean ± SEM (*p < 0.05
compared to pBx-empty). See also Table S1.of identically conserved residues in their transmembrane re-
gions, which are also found in the invertebrate ortholog, sarco-
lamban (SCL) (Figure 2A) (Magny et al., 2013). Structural
modeling of the transmembrane helices showed that all four
peptides are predicted to form alpha helical structures with res-
idues arranged in a similar spatial pattern (Figure 2B). PLN and
SLN both interact with SERCA in the membrane of the SR in a
common groove formed by the M2, M6, and M9 helices of
SERCA (Figure 2C) (Toyoshima et al., 2003, 2013; Winther
et al., 2013). Automated protein docking of the transmembrane
model of MLN with the crystal structure of SERCA revealed
that MLN aligned in the same groove that is occupied by PLN
and SLN (Figure 2C).
MLN Is Embedded in the SR Membrane and Colocalizes
with SERCA1
To examine the subcellular localization of MLN in vivo, we elec-
troporated a plasmid encoding GFP fused to MLN (GFP-MLN)
into the flexor digitorum brevis muscle of adult mice. Two-
photon laser scanning confocal microscopy allowed for the
simultaneous detection of GFP fluorescence and second har-
monic generation (SHG) to visualize the myosin A band of the
sarcomeres (Nelson et al., 2013). The GFP-MLN fusion protein
localized in a repeating pattern that alternated with the myosin598 Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc.A band and overlapped with the localiza-
tion of an mCherry-SERCA1 fusion pro-
tein within the SR (Figure 2D). This pattern
was consistent with the localization of
GFP-PLN and GFP-SLN fusion proteins
(Figure S2C). Additionally, an N-terminalHA-tagged MLN fusion protein (HA-MLN) expressed in C2C12
myoblasts was enriched in the subcellular fraction containing
SR/ER membrane proteins (Figure 2E), altogether suggesting
that MLN functions in the membrane of the SR.
In coimmunoprecipitation experiments, the HA-MLN fusion
protein formed a stable complex with SERCA1 (skeletal muscle
specific), SERCA2a (cardiac and slow skeletal muscle specific),
and SERCA2b (ubiquitous) isoforms (Figure S2D). Alanine muta-
genesis of MLN residues shared with PLN and SLN (L29A, F30A,
and F33A) abolished the ability of MLN to interact with SERCA1,
whereasmutation of charged residues (K27A, D35A) did not alter
this interaction (Figure 2F). These findings suggest that MLN,
PLN, and SLN share a common hydrophobic binding motif that
stabilizes their association with SERCA.
MLNRegulatesCa2+Handling by Inhibiting SERCAPump
Activity
PLN and SLN both function to inhibit Ca2+ reuptake into the
SR by lowering the affinity of SERCA for Ca2+, without altering
the maximal rate of Ca2+ pump activity (Vmax). To determine
if MLN regulates SERCA activity in a similar manner, we
directly measured Ca2+-dependent Ca2+-ATPase activity in
homogenates from HEK293 cells expressing SERCA1 (Fig-
ure 3A). Similar to the effects of PLN and SLN, expression of
Figure 4. Developmental and Adult Expres-
sion of MLN, PLN, and SLN in the Mouse
(A and B) Real-time PCR showing the relative
expression of MLN, PLN, SLN, and SERCA iso-
forms across multiple skeletal muscles, cardiac,
and nonmuscle tissues isolated and pooled from
three adult 8-week-old C57Bl/6 male mice. See
also Figure S3.MLN caused a significant reduction in the rate of Ca2+ uptake,
measured as an increase in KCa (Figure 3A; Table S1). Coex-
pression of the full-length RNA encoding MLN (MLN RNA) re-
sulted in a similar decrease in Ca2+ uptake compared to a vec-
tor containing only the MLN coding sequence (Figure 3B). The
activity of the MLN RNA was abolished by introduction of a
frameshift mutation to disrupt the expression of the MLN micro-
peptide (MLN-RNA-FS), demonstrating that the RNA itself does
not inhibit SERCA activity (Figure 3B). No effects on Vmax were
observed under any conditions tested, and the addition of
thapsigargin, a potent inhibitor of SERCA activity, abolished
Ca2+ uptake (Figure 3A).
Because the concentration of SR Ca2+ is dependent upon
SERCA reuptake activity, we examined if MLN overexpression
could alter SR Ca2+ levels in C2C12 myoblasts. SR Ca2+ levels
were directly measured using retroviral delivery of the fluores-
cence resonance energy transfer (FRET)-based, SR-localized
Ca2+ sensor T1ER, using culture conditions previously shown
to be sensitive to changes in endogenous SERCA activity
(Brandman et al., 2007). Coexpression of MLN or SLN sig-
nificantly decreased the levels of SR Ca2+, measured as a
decrease in T1ER FRET (Figure 3C). We alternatively compared
SR Ca2+ levels using the ratiometric Ca2+ indicator dye fura-2-
AM, following SR Ca2+ release using the RyR agonist 4-chloro-
m-cresol (4-CMC) (Figure 3D). Consistent with our previous
findings, overexpression of MLN or SLN significantly decreased
peak Ca2+ release from the SR (Figure 3D). Together, theseCell 160, 595–606,findings demonstrate that MLN inhibits
SERCA pump kinetics similar to PLN
and SLN.
MLN, PLN, and SLN Are Expressed
in Different Striated Muscle Types
The structural and functional similarities
between MLN, PLN, and SLN suggest
they comprise a family of micropeptides
that regulate Ca2+ handling through mod-
ulation of SERCA activity. To determine if
PLN or SLN are functionally redundant
with MLN in vivo, we examined their
expression during developmental and
adult stages. In the heart, PLN expression
was detectable in both the atria and
ventricles, whereas SLN expression was
specific to the atria (Figures 4A and
S3A). SLN overlapped with the expres-
sion of MLN in fetal skeletal muscles,
which display a slow phenotype duringembryonic development (Figure S3A) (Lu et al., 1999). Consistent
with previous reports, quantitative real-time PCR and RNA
sequencing (RNA-seq) expression analyses revealed that SLN
was markedly downregulated in most adult skeletal muscles,
which convert to fast type in themouse (Figures 4A and S3B) (Tu-
pling et al., 2011). In contrast, MLN was robustly expressed in all
adult skeletal muscles, similar to the expression pattern of
SERCA1 (Figures 4A and 4B). The expression patterns of PLN
and SLN were more similar to the expression of SERCA2, which
is highly expressed in cardiac and slow skeletal muscles (Fig-
ure 4B). In addition, comparison of RNA-seq expression data re-
vealed that PLN and SLN are not expressed in differentiated
C2C12 myotubes, whereas MLN transcripts are robustly ex-
pressed (Figure S3C). Thus,MLN, PLN, and SLN are differentially
expressed across vertebrate muscle types, andMLN is the most
abundant of the three micropeptides expressed in adult skeletal
muscle of the mouse.
Transcriptional Control of MLN Expression by MyoD
and MEF2
MLN and the skeletal muscle-specific isoforms of SERCA and
RyR are coregulated by MyoD, suggesting they comprise a
core genetic module important for Ca2+ handling in skeletal mus-
cle (Fong et al., 2012). Analysis of the 50 flanking region of the
MLN gene revealed highly conserved binding sites for the
myogenic transcription factors MyoD (E-box) and MEF2 (Fig-
ure S4A), which bound specifically to these sequences in gelFebruary 12, 2015 ª2015 Elsevier Inc. 599
Figure 5. Regulation of MLN Transcription by MyoD and MEF2
(A) A fragment of theMLN promoter (506 to +86, relative to the transcriptional
start site) containing a highly conservedMyoD E-box (CACCTG) andMEF2 site
(CTAATAACAG) was cloned in front of the luciferase reporter gene (MLN-Luc).
The MLN-Luc reporter was robustly transactivated by the skeletal muscle
transcription factors MyoD and MEF2 in COS7 cells (gray and red bars,
respectively). Mutation of the E-box (acCCgt) or Mef2 site (CTgggAACAG)
600 Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc.mobility shift assays (Figure S4B). MyoD and MEF2 indepen-
dently activated a luciferase reporter linked to the proximal
MLN promoter (MLN-Luc), and transactivation was lost upon
mutagenesis of their respective binding sites (Figure 5A). Chro-
matin immunoprecipitation sequencing (ChIP-seq) data at this
locus revealed that MyoD bound specifically to this region in
both C2C12 myoblasts and myotubes (Figure S4C) (Bernstein
et al., 2012). The activity of the MLN-Luc promoter in C2C12
myoblasts and myotubes was similarly dependent upon both
the MEF2 and E-box sequences, which, when mutated, resulted
in the loss and abrogation of MLN promoter activation, res-
pectively (Figure 5B). Consistent with this, a LacZ transgene
controlled by the MLN promoter (MLN-lacZ) displayed skeletal
muscle-specific expression in vivo and was dependent upon
the MEF2 and E-box sequences for full promoter activation (Fig-
ure 5C). Thus, the MLN gene is a direct target of the core tran-
scription factors that activate skeletal myogenesis.
Generation of MLN Knockout Mice Using TALENs
To investigate the function of MLN in vivo, we generated MLN
knockout (KO) mice using TAL effector nuclease (TALEN)-medi-
ated homologous recombination. A unique TALEN pair specific
for exon 1 of theMLN locus was designed and constructed using
the REAL assembly method (Reyon et al., 2012). A loss-of-func-
tion allele was created using a donor plasmid to insert a red fluo-
rescent reporter (tdTomato), followed by a triple polyadenylation
cassette into exon 1 in the MLN locus (Figure 6A). This strategy
was designed to prematurely terminate transcription upstream
of the MLN coding sequence but allow for the expression of
a red fluorescent reporter by the endogenous MLN promoter.
Correct targeting was verified by Southern blot and PCR-based
genotyping (Figures 6B and S5A). Detection of tdTomato fluores-
cence in MLN KO mice was specific to skeletal muscle and was
not detected in other tissues (Figure 6C). qPCR using primer
pairs specific to the downstream exons 2 and 3 demonstrated
that the MLN transcript was absent in skeletal muscle from
MLN KO mice (Figure 6D).
MLN KO mice were born at expected Mendelian ratios from
heterozygous intercrosses and showed no obvious morpholog-
ical abnormalities or differences in body or muscle weights (Fig-
ure S5B). Mice lacking PLN and SLN also have nonpathological
phenotypes but show enhanced Ca2+ handling and contractility
in cardiac and slow skeletal muscle (Luo et al., 1994; MacLennan
and Kranias, 2003; Tupling et al., 2011).(indicated by an X) abrogated transactivation by MyoD:E12 heterodimer or
Mef2c, respectively. All luciferase values were normalized to the trans-
activation of a basal luciferase reporter (TATA-Luc) with MyoD or Mef2,
respectively. Data are presented as mean ± SEM.
(B) Luciferase reporter assays showing thatMEF2 and E-box enhancer binding
sites are essential for transactivation of theMLN promoter in C2C12myoblasts
and myotubes. Data are presented as mean ± SEM.
(C) X-gal and H&E staining of E10.5 mouse embryos harboring either the MLN
promoter-lacZ transgene (WT) or mutations in the MLN promoter (DMef2 or
DE-box). The MLN promoter showed expression in the myotomal compart-
ment of the somites (orange arrow) and premyogenic cells in the mandibular
arch (red arrow). Mutation of the MEF2 or E-box sequences in the MLN pro-
moter-lacZ transgene abrogated or abolished muscle-specific expression.
See also Figure S4.
Figure 6. Generation and Characterization
of MLN Knockout Mice
(A) TALEN-mediated homologous recombination
was used to insert a tdTomato fluorescent reporter
and triple polyadenylation cassette into exon 1 of
the MLN locus to generate a null allele. A sche-
matic of the donor vector and targeting strategy is
shown. P, PvuII.
(B) Southern blot analysis confirming correct tar-
geting of the tdTO-triple polyadenylation cassette
into exon 1 of theMLN locus using probes 50 and 30
to the TALEN cut site.
(C) tdTomato fluorescence was specific to skeletal
muscle (white arrowhead) ofMLNKOmice and not
detected in other tissues, such as tendon (blue
arrowhead).
(D) Real-time PCR using primers specific to exons
2 and 3 demonstrating absence of MLN tran-
scripts in MLN KO muscle, as well as in liver.
(E) Muscle performance was measured using
forced treadmill running to exhaustion. MLN KO
(n = 15) mice ran31% longer thanWT littermates
(n = 14).
(F) Comparison of distance run by MLN KO and
WT mice in Figure 6E.
(G) Myoblasts isolated and cultured from MLN KO
hindlimb muscles were imaged using Fura-2-AM
and treated with the RyR agonist 4-CMC in the
absence of extracellular Ca2+ to indirectly mea-
sure SR Ca2+ levels. MLN KO myoblasts showed
significantly increased SR Ca2+ levels, measured
as peak Ca2+ release from the SR. Data are pre-
sented as mean ± SEM (*p < 0.05 compared toWT
as in E and F and pBx-empty in G).
See also Figure S5.Enhanced Ca2+ Handling and Skeletal Muscle
Performance in MLN KO Mice
To examine the potential role of MLN in regulating skeletal mus-
cle performance, we subjected 8-week-old wild-type (WT) and
MLNKOmice to a regimen of forced treadmill running to exhaus-
tion. Remarkably, MLN KO mice ran an average time of 31%
longer than their WT littermates, representing a 55% increase
in running distance (Figures 6E and 6F). Mice with a fast-to-
slow fiber type switch also show increased running performance
(van Rooij et al., 2009). However, histological analyses of hind-
limb muscles, including quadriceps (fast-type) and soleus
(slow-type) muscles revealed no obvious differences in fiber-
type identity or myofiber size between WT and MLN KO mice
(Figures S5C–S5E), indicating that MLN functions through a
different mechanism to regulate muscle performance.Cell 160, 595–606,Next, we investigated whether SR Ca2+
levels were altered in primary myoblasts
isolated from hindlimb muscles of MLN
KO versus WT littermates. SR Ca2+ levels
were measured using the calcium indica-
tor fura-2-AM and SR Ca2+ release by
the addition of the RyR agonist 4-CMC.
Strikingly, MLN KO myoblasts showed
significantly increased SR Ca2+ levels
compared to WT myoblasts, measuredas peak SR Ca2+ release (Figure 6G). This increase occurred
without changes in the expression of RyR1 and SERCA1 expres-
sion between WT and MLN KOmuscles (Figure S5F), consistent
with the function of MLN as an inhibitor of SERCA activity.
Together, these findings support the function of MLN as the
dominant regulator of SERCA activity in adult skeletal muscle.
DISCUSSION
SERCA is a key regulator of striated muscle performance by
serving as the major Ca2+ ATPase responsible for the reuptake
of cytosolic Ca2+ into the SR (Figure 7A). Direct modulation of
SERCA pump activity by the micropeptides PLN and SLN regu-
lates muscle contractility by diminishing the rate of Ca2+ reup-
take into the SR. However, because PLN and SLN are notFebruary 12, 2015 ª2015 Elsevier Inc. 601
Figure 7. A Family of SERCA-Inhibitory Micropeptides
(A) RyR and SERCA play a critical role in muscle contractility by controlling
Ca2+ cycling between the cytosol and SR. MLN, PLN, and SLN inhibit SERCA
pump activity in different striated muscle types of vertebrates.
(B) Illustration of the family of SERCA-inhibitory micropeptides. The discovery
of MLN reveals that vertebrates encode three SERCA inhibitory peptides
that share conserved residues within their transmembrane alpha helices.
Green shading denotes identical residues, and blue shading denotes similar
residues. MLN, myoregulin; PLN, phospholamban; SLN, sarcolipin; SCL,
sarcolamban.expressed in most adult skeletal muscles of mice, the possible
existence of other SERCA regulatory factors has remained an
open question.
Our biochemical and in vivo results show that MLN forms
a stable complex with SERCA in the membrane of the SR
and that MLN directly influences SR Ca2+ levels and maximal602 Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc.exercise performance. The robust skeletal muscle-specific ex-
pression of MLN, resulting from direct transactivation by the
myogenic transcription factorsMyoD andMEF2, further highlight
MLN as the predominant SERCA regulating micropeptide in
adult skeletal muscle. The discovery of MLN reveals a universal
mechanism for the control of SERCA activity by a family of
related micropeptides expressed in different striated muscle
types in vertebrates (Figure 7A).
Micropeptides Can Be Concealed within RNAs
Misannotated as Noncoding
Micropeptides remain highly underrepresented in genome anno-
tations due in large part to the difficulty in identifying functional
short ORFs in RNA transcripts. Recent advances in bioinformatic
and biochemical methodologies have revealed that lncRNAs
may harbor concealed micropeptides; however, only a few
have been functionally verified and characterized in vivo. Here,
we have identified and characterized the function of a conserved
micropeptide in vertebrates that functions as an important regu-
lator of skeletal muscle performance throughmodulation of Ca2+
handling by SERCA. Given the attention that has been focused
on the control of SERCA activity and muscle function over the
years, it is remarkable that such a key regulator of these pro-
cesses has gone undetected. Undoubtedly, this is because the
MLN ORF is concealed in an RNA annotated as noncoding.
Our discovery of MLN was possible due to its high sequence
conservation in vertebrates and the presence of an identifiable
functional domain, a type II transmembrane alpha helix. We
found that the MLN alpha helix shares residues in common
with PLN and SLN; however, common bioinformatic search tools
alone are not sufficient to identify the relatedness of MLN, PLN,
and SLN. Interestingly, both PLN and SLN were first discovered
as micropeptides and subsequently mapped to RNA transcripts
(Kirchberber et al., 1975; Wawrzynow et al., 1992). The PLN and
SLN genes share a genomic architecture similar to that of MLN,
in which the small ORFs are encoded in the 50 region of the ter-
minal exon. Indeed, the transcripts encoding PLN and SLN may
have also been annotated as noncoding, if not for their prior dis-
covery as micropeptides.
A Family of SERCA-Inhibitory Micropeptides
In Drosophila, the invertebrate ortholog of SERCA is encoded by
a single gene (Ca-P60A) and is modulated by the recently iden-
tified micropeptide sarcolamban (SCL) (Magny et al., 2013). In
vertebrates, the SERCA family has expanded to encode three
genes (SERCA1-3) that give rise to multiple alternate splice var-
iants with differing kinetic properties and expression patterns
(Anger et al., 1994; Periasamy and Kalyanasundaram, 2007).
The expansion of vertebrate gene families occurred through
whole-genome and gene-duplication events, resulting in the for-
mation of paralogous gene families. Combined with the tissue-
specific expression patterns of the individual SERCA isoforms,
the differential expression of MLN, PLN, and SLN likely contrib-
utes to the unique Ca2+ handling and contractile properties of
different striated muscle types in vertebrates. In addition, the
extent to which MLN, PLN, and SLN partially overlap in their
expression in different muscle types may influence the calcium
kinetics and performance of these tissues. Coexpression of
PLN and SLN in atrial cardiomyocytes and slow skeletal muscle
has been shown to result in the superinhibition of SERCA pump
activity (MacLennan et al., 2003). MLN expression overlaps with
that of PLN and SLN in adult slow skeletal muscle and with SLN
in developing skeletal muscles. Future biochemical and animal
studies are required to determine the extent to which MLN syn-
ergizes with PLN and SLN in coregulating SERCA activity in
slow-type and developing skeletal muscle. SLN expression
in larger animals is more widespread than in rodents, occurring
in both fast- and slow-type muscles (Fajardo et al., 2013; Oder-
matt et al., 1997). A synergistic interaction between MLN and
SLN may be more biologically relevant in the adult tissues of
these species; however, the relative expression patterns of these
two genes in these species remain to be determined.
Apart from spatiotemporal differences in expression, the
SERCA-regulatory peptides differ in size and presence of addi-
tional secondary structures. A schematic illustration of the family
of SERCA-inhibitory micropeptides is shown in Figure 7B. Both
SLN and SCL lack extended N-terminal regions and additional
secondary structures other than their transmembrane alpha he-
lices. MLN and PLN have expanded N-terminal cytoplasmic re-
gions that encode a beta sheet and alpha helix, respectively. The
N-terminal sequence of PLN has been shown to be critical for its
function, and phosphorylation of serine-16 by protein kinase A
(PKA) or threonine-17 by Ca2+/calmodulin-dependent protein ki-
nase II (CaMKII) diminishes the ability of PLN to inhibit SERCA
activity (Mattiazzi et al., 2006; Wegener et al., 1989). The N-ter-
minal sequence of MLN could serve as a similar regulatory
domain through phosphorylation, as this sequence contains
multiple serine and threonine residues. Deciphering the physio-
logical signaling pathways that regulate MLN expression and
function will be important to fully understand its role in skeletal
muscle development and disease.
Future Questions
Defects in Ca2+ signaling underlie the pathogenesis of many
muscle diseases that arise from mutations in components of
Ca2+ signaling pathways, as well as diseases that arise from a
loss of myofiber structural integrity (Berchtold et al., 2000; Millay
et al., 2008). Given the importance of SERCA pump activity in
regulating Ca2+ handling and the pathogenesis of skeletal mus-
cle diseases, such as Brody myopathy and muscular dystro-
phies (Allen et al., 2010; Goonasekera et al., 2011; Odermatt
et al., 1996), the discovery of MLN opens interesting possibilities
for themodulation of these pathways. Considering the enhanced
exercise capacity of MLN KO mice, it is interesting to speculate
that pharmacologic approaches to disrupt the association of
MLNwith SERCAmight have similar salutary effects. Modulation
of SERCA activity in skeletal muscle has also been implicated in
the control of systemic energy homeostasis (Bal et al., 2012),
raising the interesting possibility that MLN may exert additional
metabolic functions. Considering that SERCA is also important
in Ca2+ regulation in nonmuscle cell types in which MLN, PLN,
and SLN are not expressed, it is interesting to speculate that
additional SERCA-modulating micropeptides may be concealed
within putative lncRNAs expressed in other tissues. Finally, the
discovery of MLN as a previously unrecognized regulator of
muscle function suggests that the microproteome, which islargely unexplored, represents a reservoir for future biological
insights.
EXPERIMENTAL PROCEDURES
TALEN-Mediated Homologous Recombination in Mice
A unique TALEN pair specific for the MLN locus was designed using the ZiFiT
Targeter Program (http://zifit.partners.org/ZiFiT/Introduction.aspx) and con-
structed using the REAL Assembly Kit (Addgene) (Reyon et al., 2012). A donor
vector containing the tdTomato reporter and triple polyadenylation sequences
was constructed by incorporating short 50 and 30 homology arms specific to
the MLN locus. TALEN mRNAs were in vitro transcribed using the mMessage
mMachine T7Ultra Kit (Life Technologies), diluted to 25 ng ml1, and coinjected
with 3 ng ml1 of the circular DNA donor plasmid into the nucleus and cyto-
plasm of one-cell-stage embryos (B6C3F1) and transferred into pseudopreg-
nant female ICR mice.
Study Approval
All experimental procedures involving animals in this study were reviewed and
approved by the University of Texas Southwestern Medical Center’s Institu-
tional Animal Care and Use Committee.
Radioisotopic In Situ Hybridization
In situ hybridizations were performed as previously described (Shelton et al.,
2000). See the Extended Experimental Procedures for a more detailed proto-
col. The primer sequences used to cloneMLN, PLN, and SLN cDNA templates
are listed in Table S2.
CRISPR/Cas9-Mediated Homologous Recombination in C2C12
Myoblasts
A single-guide RNA (sgRNA) specific to the C-terminal coding sequence of the
mouse MLN locus was cloned into the sgRNA/Cas9 expression vector px330
(MLN-FLAG-px330). The donor vector was constructed with a single FLAG
epitope tag in-frame with the MLN coding sequence flanked by 500 base
pair homology arms specific to the MLN locus. MLN-FLAG knockin clones
were generated by transient cotransfection and expanded from single-cell
clones. Detection of endogenous MLN-FLAG peptide was performed by
immunoblotting with a rabbit anti-FLAG antibody (Sigma) on protein lysates
immunoprecipitated with mouse anti-FLAG agarose beads (Sigma).
Treadmill Running
In blinded studies, male MLN KO and WT littermate mice were subjected to
forced exercise on a treadmill (Exer-6M, Columbus Instruments, 10% incline)
at 8 weeks of age using a regimen previously described (van Rooij et al., 2009).
See the Extended Experimental Procedures for a more detailed protocol.
Intracellular Ca2+ Imaging
CytosolicCa2+ levels weremeasured as describedpreviously (Liou et al., 2005),
with the exception that retroviral-transduced C2C12 cells or primarymyoblasts
were plated on Ibidi m-35mm tissue-culture dishes and cultured for 24 hr in low
Ca2+ (0.1mMCa2+) prior to imaging to increasesensitivity to changes inSRCa2+
levels (Brandman et al., 2007). SR Ca2+ levels were directly measured using
T1ER as previously described (Abell et al., 2011; Tsai et al., 2014). See the
Extended Experimental Procedures for a more detailed protocol.
Oxalate-Supported Ca2+ Uptake Measurements in HEK293 Lysates
Oxalate-supported Ca2+-dependent Ca2+-ATPase activity in homogenates
was measured by a modification of the Millipore filtration technique as
described previously (Holemans et al., 2014; Luo et al., 1994). HEK293 cells
were cotransfected with equal amounts of an expression plasmid encoding
mouse SERCA1 and an expression plasmid encoding MLN, PLN, or SLN.
See the Extended Experimental Procedures for a more detailed protocol.
Coimmunoprecipitations and Western Blot Analysis
Coimmunoprecipitations (coIPs) were performed as previously described
(Anderson et al., 2009). Tris-tricine-SDS-PAGE was carried out using 16.5%Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc. 603
Tris-tricine gels (BioRad) and Tris-tricine-SDS running buffer (BioRad). See the
Extended Experimental Procedures for a more detailed protocol.
Real-Time PCR
Total RNA was prepared from whole muscles using Trizol (Invitrogen) and
treated with DNase prior to reverse transcription by Superscript III (Invitrogen).
Real-timePCRwasperformed using TaqManprobes (ABI) or SYBRgreenusing
primers in Table S2. TaqMan probes include Mck (Mm00432556_m1), Mef2c
(Mm01340842_m1), SLN (Mm00481536_m1), PLN (Mm00452263_m1), and
SERCA2 (Mm01201434_m1). Primers for SYBR green reactions are listed in
Table S2.
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assays (EMSAs) were performed as previously
described (Anderson et al., 2012) using recombinant myc-tagged proteins ex-
pressed inCOS7cells anddouble-strandedEMSAprobes createdbyannealing
complementary oligonucleotides. Probe sequences are listed in Table S2.
Supershiftswereperformedbyadding1mgofmouseanti-Mycantibody (Invitro-
gen). See the Extended Experimental Procedures for a more detailed protocol.
Luciferase Assays
Luciferase assays were performed as previously described (Anderson et al.,
2009). Luciferase activity was measured using a FluoStar OPTIMA microplate
reader (BMG Labtech) and normalized to beta-galactosidase activity using the
FluoReporter LacZ/Galactosidase Quantitation Kit (Invitrogen). See the
Extended Experimental Procedures for a more detailed protocol.
Subcellular Fractionation
C2C12 myoblasts infected with a retrovirus encoding the HA-MLN fusion pro-
tein (pBabeX-HA-MLN) were fractionated as previously described (Millay et al.,
2013). See the Extended Experimental Procedures for a more detailed
protocol.
Northern and Southern Blot Analysis
Northern blots were performed using a commercially prepared adult mouse
multitissue RNA blot (MN-MT-1; Zyagen) hybridized with a radiolabeled DNA
probe specific to the full-length MLN transcript. Radiolabeled DNA probes
for northern and Southern blots were generated using a RadPrime Kit (Invitro-
gen) (Table S2).
Histology and Immunohistochemistry
Skeletal muscle tissues were dissected and fixed overnight in 4% formalde-
hyde in PBS prior to paraffin embedding and sectioning using routine proce-
dures. Immunohistochemistry was performed on deparaffinized sections
using a HistoMouse-Plus kit (Invitrogen) using primary antibodies specific to
fast (MY32; Sigma) and slow (NOQ7.54; Sigma) myosins. Wheat germ agglu-
tinin (WGA) staining was performed using Alexa Fluor 555-conjugated WGA
(Invitrogen) as described previously (Liu et al., 2011).
Analysis of RNA-Seq Expression Data
Raw data for C2C12 cells and triceps brachii muscle were downloaded from
the Short Read Archive (SRP002119 and SRP008123, respectively). Reads
were mapped to the UCSC mm9 genome annotation using TopHat, and align-
ments were processed to bigWig coverage maps and viewed using the UCSC
genome browser.
Circular Dichroism Spectroscopy
Circular dichroism (CD) spectroscopy measurements were performed using a
JASCO J-815 spectrometer on in vitro-synthesized full-length MLN (Peptide
2.0). The secondary structure elements were calculated using Yang’s fit. The
root-mean-square deviation for the observed and calculated CD spectra
values was 3%. See the Extended Experimental Procedures for a more
detailed protocol.
Structural Modeling and Automated Protein Docking
The helical domains of MLN, PLN, SLN, and SCL were created ab initio using
I-TASSER (Zhang, 2008). Automated protein docking of the MLN model with604 Cell 160, 595–606, February 12, 2015 ª2015 Elsevier Inc.the crystal structure of SERCA1 (4H1W) was performed using ClusPro 2.0
(Comeau et al., 2004).
Adult Muscle Electroporation and Imaging
Flexor digitorum brevis (FDB) muscles of 12-week-oldmalemice were electro-
porated as previously described (Nelson et al., 2013), with expression vectors
encoding N-terminal GFP fusions to MLN, PLN, or SLN. Unfixed FDB muscles
were examined directly using two-photon laser scanning microscopy (Zeiss;
LSM 780), with reverse second harmonic generation to visualize the A bands
as an internal reference. See the Extended Experimental Procedures for a
more detailed protocol.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2015.01.009.
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